Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk

Circulation Journal

Volumn 77, Issue 12, 2013, Pages 3023-3028

  Okada, Sadanori ^a   Morimoto, Takeshi ^b   Ogawa, Hisao ^c   Sakuma, Mio ^b   Soejima, Hirofumi ^c   Nakayama, Masafumi ^c   Sugiyama, Seigo ^c   Jinnouchi, Hideaki ^d   Waki, Masako ^e   Doi, Naofumi ^a   Horii, Manabu ^a   Kawata, Hiroyuki ^a   Somekawa, Satoshi ^a   Soeda, Tsunenari ^a   Uemura, Shiro ^a   Saito, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d Jinnouchi Hospital   (Japan)

^e SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

Author keywords

Aspirin; Cardiovascular risk factors; JPAD trial; Primary prevention; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING;

ADULT; AGE FACTORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84888269737     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0307     Document Type: Article

References (25)

1. Brun E, Nelson RG, Bennett PH, Imperatore G, Zoppini G, Verlato G, et al. Diabetes duration and cause-specifc mortality in the Verona Diabetes Study. Diabetes Care 2000; 23: 1119-1123.
2. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Cause-specifc mortality in a population with diabetes: South Tees Diabetes Mortality Study. Diabetes Care 2002; 25: 43-48.
3. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010; 74: 597-607.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
5. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849-1860.
6. JCS Joint Working Group. Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). Circ J 2013; 77: 231-248.
7. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: Meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531.
8. Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB, et al. Aspirin for the primary prevention of cardiovascular events: A systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009; 32: 2300-2306.
9. Pignone M, Williams CD. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol 2010; 6: 619-628.
10. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientifc statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694-2701.
11. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientifc statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010; 33: 1395-1402.
12. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55: 2878-2886.
13. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635-1701.
14. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008; 300: 2134-2141.
15. Nieto FJ, Coresh J. Adjusting survival curves for confounders: A review and a new method. Am J Epidemiol 1996; 143: 1059-1068.
16. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract 2010; 87: 211-218.
17. Nemerovski CW, Salinitri FD, Morbitzer KA, Moser LR. Aspirin for primary prevention of cardiovascular disease events. Pharmacother-apy 2012; 32: 1020-1035.
18. Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular fltration rate: Subanalysis from the JPAD trial. Diabetes Care 2011; 34: 280-285.
19. Okada S, Morimoto T, Ogawa H, Kanauchi M, Nakayama M, Uemura S, et al. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: A subanalysis of the JPAD trial. Diabetes Care 2011; 34: 1277-1283.
20. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
21. Igarashi Y, Chikamori T, Hida S, Tanaka H, Shiba C, Usui Y, et al. Importance of the ankle-brachial pressure index in the diagnosis of coronary artery disease in women with diabetes without anginal pain. Circ J 2011; 75: 2206-2212.
22. Soejima H, Morimoto T, Saito Y, Ogawa H. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. Thromb Haemost 2010; 104: 1085-1088.
23. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000; 342: 1-8.
24. Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke 2000; 31: 1588-1601.
25. Morimoto T, Fukui T, Lee TH, Matsui K. Application of U.S. guidelines in other countries: Aspirin for the primary prevention of cardiovascular events in Japan. Am J Med 2004; 117: 459-468.